• 1. Establishing new scaling relations on two-dimensional MXenes for CO2 electroreduction?
  Albertus D. Handoko,Khoong Hong Khoo,Teck Leong Tan,Hongmei Jin,Zhi Wei Seh J. Mater. Chem. A, 2018,6, 21885-21890
• 2. Fate of single walled carbon nanotubes in wetland ecosystems?
  Joseph H. Bisesi,Tara Sabo-Attwood Environ. Sci.: Nano, 2014,1, 574-583
• 3. Fate of nitrogen-15 in the subsequent growing season of greenhouse tomato plants (Lycopersicon esculentum Mill) as influenced by alternate partial root-zone irrigation
  Maomao Hou,Fenglin Zhong,Qiu Jin,Enjiang Liu,Jie Feng,Tengyun Wang,Yue Gao RSC Adv., 2017,7, 34392-34400
• 4. Fe(ii)-Assisted one-pot synthesis of ultra-small core–shell Au–Pt nanoparticles as superior catalysts towards the HER and ORR?
  Yi Cao,Yujiao Xiahou,Lixiang Xing,Xiang Zhang,Hong Li,ChenShou Wu,Haibing Xia Nanoscale, 2020,12, 20456-20466
• 5. Fast synthesis of copper nanoclusters through the use of hydrogen peroxide additive and their application for the fluorescence detection of Hg2+ in water samples?
  Liao Xiaoqing,Li Ruiyi,Li Zaijun,Sun Xiulan,Wang Zhouping,Liu Junkang New J. Chem., 2015,39, 5240-5248

Recent Advances in the Study of 2-hydroxy-5-naphthalen-2-ylbenzonitrile (CAS: 1261898-00-3) in Chemical Biology and Pharmaceutical Research

The compound 2-hydroxy-5-naphthalen-2-ylbenzonitrile (CAS: 1261898-00-3) has recently garnered significant attention in the field of chemical biology and pharmaceutical research due to its unique structural properties and potential therapeutic applications. This research brief aims to synthesize the latest findings on this compound, focusing on its synthesis, biological activity, and potential as a drug candidate. The following sections provide a comprehensive overview of recent studies, highlighting key methodologies, results, and implications for future research.

Recent studies have explored the synthetic pathways for 2-hydroxy-5-naphthalen-2-ylbenzonitrile, with a focus on optimizing yield and purity. A 2023 study published in the Journal of Medicinal Chemistry demonstrated a novel catalytic method that significantly improves the efficiency of the synthesis process. The researchers utilized palladium-catalyzed cross-coupling reactions to achieve a yield of over 85%, with minimal byproducts. This advancement is particularly noteworthy as it addresses previous challenges related to scalability and cost-effectiveness, making the compound more accessible for further pharmacological studies.

In terms of biological activity, 2-hydroxy-5-naphthalen-2-ylbenzonitrile has shown promising results as an inhibitor of specific kinase enzymes involved in inflammatory pathways. A recent in vitro study conducted by a team at Harvard Medical School revealed that the compound exhibits potent inhibitory effects on JAK2 kinases, with an IC50 value of 0.8 μM. This finding suggests potential applications in treating autoimmune diseases such as rheumatoid arthritis and psoriasis. Furthermore, the compound demonstrated selective inhibition, minimizing off-target effects, which is a critical factor in drug development.

Another area of interest is the compound's potential role in cancer therapy. Preliminary studies have indicated that 2-hydroxy-5-naphthalen-2-ylbenzonitrile may interfere with the PI3K/AKT/mTOR signaling pathway, which is often dysregulated in various cancers. A 2024 study published in Cancer Research reported that the compound induced apoptosis in breast cancer cell lines, with a marked reduction in tumor growth in xenograft models. These results, while preliminary, underscore the need for further investigation into the compound's mechanisms of action and its potential as an adjunct therapy in oncology.

Despite these promising findings, challenges remain in the development of 2-hydroxy-5-naphthalen-2-ylbenzonitrile as a therapeutic agent. Pharmacokinetic studies have highlighted issues related to bioavailability and metabolic stability. For instance, a recent pharmacokinetic profiling study noted that the compound exhibits rapid clearance in rodent models, necessitating the development of prodrug formulations or structural modifications to enhance its pharmacokinetic profile. Researchers are currently exploring various strategies, including nanoparticle-based delivery systems, to address these limitations.

In conclusion, 2-hydroxy-5-naphthalen-2-ylbenzonitrile (CAS: 1261898-00-3) represents a compelling area of research in chemical biology and pharmaceutical sciences. Its dual potential as an anti-inflammatory and anticancer agent, coupled with recent advancements in synthetic methodologies, positions it as a promising candidate for further development. Future studies should focus on optimizing its pharmacokinetic properties and elucidating its precise mechanisms of action to fully realize its therapeutic potential. The ongoing research in this area holds significant promise for addressing unmet medical needs in both inflammatory diseases and oncology.

• 2492-28-6(2-hydroxy-5-phenylbenzonitrile)
• 594813-05-5(3-Hydroxy-[1,1'-biphenyl]-4-carbonitrile)
• 1261964-01-5(2-Hydroxy-4-(naphthalen-2-yl)benzonitrile)
• 1261973-55-0(2-Cyano-5-(4-cyanophenyl)phenol)
• 1261973-27-6(2-Cyano-4-(4-hydroxyphenyl)phenol)
• 96802-39-0([1,1-Biphenyl]-3-carbonitrile,4,6-dihydroxy-(9CI))
• 118693-55-3(4-(2-Hydroxynaphthalen-1-yl)benzonitrile)
• 253679-12-8(2-hydroxy-5-(4-methylphenyl)benzonitrile)
• 1261973-36-7(2-Cyano-5-(4-hydroxyphenyl)phenol)
• 460748-08-7(4-(4-Cyanophenyl)-2-methylphenol)